• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植患者移植后红细胞增多症的相关因素评估

Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients.

作者信息

Ahmed Saima, Ahmed Ejaz, Naqvi Rubina, Qureshi Sehar

机构信息

Department of Nephrology, Sindh Institute of Urology and Transplantation, Karachi.

出版信息

J Pak Med Assoc. 2012 Dec;62(12):1326-9.

PMID:23866484
Abstract

OBJECTIVE

To evaluate the prevalence and contributing factors causing post transplant erythrocytosis in renal transplant patients.

METHODS

This retrospective study was conducted on live related renal transplant patients at SIUT. The records of all transplant recipients transplanted between April 2008 and December 2008 and who had at least 24 months follow up were studied. Patients in whom haematocrit exceeded 51% and those who received treatment for it were classified into post transplant erythrocytosis group.

RESULTS

Out of 200 renal transplant patients who had functioning graft at the time of analysis, 40 (20%) developed post transplant erythrocytosis (HCT > or = 51%) after a mean interval of 9.5 +/- 2.5 months. Patients with erythrocytosis were mostly males (95% in PTE group vs 73.75% in non PTE group), had a shorter period on dialysis before undergoing renal transplantation (9.28 months in PTE group vs 14.56 months in non PTE group) and had relatively better graft function at the onset of erythrocytosis as judged by serum creatinine (S. Creatinine of 1.06 +/- 0.29 mg/dl in PTE group vs 1.37 +/- 0.51 mg/dl in non PTE group). No thrombotic complications were observed. All patients with erythrocytosis were treated with enalapril (ACE inhibitors) and 28 out of 40 required phlebotomy in addition to ACE inhibitors. The mean HCT at the time of last follow up in treated patients was 48.61 +/- 1.85%.

CONCLUSION

Post transplant erythrocytosis generally occurs in male patients with good graft function, thrombotic complications are of rare occurrence and response to ACE inhibitors is good.

摘要

目的

评估肾移植患者移植后红细胞增多症的患病率及相关影响因素。

方法

本回顾性研究针对在卡拉奇大学医学科学研究所(SIUT)接受亲属活体肾移植的患者开展。研究了2008年4月至2008年12月期间接受移植且至少随访24个月的所有移植受者的记录。将血细胞比容超过51%的患者以及接受过相关治疗的患者归入移植后红细胞增多症组。

结果

在分析时移植肾功能良好的200例肾移植患者中,40例(20%)在平均9.5±2.5个月的间隔期后发生了移植后红细胞增多症(血细胞比容≥51%)。红细胞增多症患者大多为男性(移植后红细胞增多症组为95%,非移植后红细胞增多症组为73.75%),肾移植前透析时间较短(移植后红细胞增多症组为9.28个月,非移植后红细胞增多症组为14.56个月),且根据血清肌酐判断,红细胞增多症发作时移植肾功能相对较好(移植后红细胞增多症组血清肌酐为1.06±0.29mg/dl,非移植后红细胞增多症组为1.37±0.51mg/dl)。未观察到血栓形成并发症。所有红细胞增多症患者均接受依那普利(一种血管紧张素转换酶抑制剂)治疗,40例中有28例除接受血管紧张素转换酶抑制剂治疗外还需要进行放血治疗。治疗患者末次随访时的平均血细胞比容为48.61±1.85%。

结论

移植后红细胞增多症一般发生在移植肾功能良好的男性患者中,血栓形成并发症罕见,对血管紧张素转换酶抑制剂反应良好。

相似文献

1
Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients.肾移植患者移植后红细胞增多症的相关因素评估
J Pak Med Assoc. 2012 Dec;62(12):1326-9.
2
Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study.肾移植术后红细胞增多症的易感因素。一项前瞻性配对对照研究。
Clin Nephrol. 1996 Feb;45(2):83-9.
3
Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.血管紧张素转换酶抑制剂依那普利对移植后红细胞增多症的影响。
Hiroshima J Med Sci. 1998 Sep;47(3):121-4.
4
Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.沙特阿拉伯王国吉达肾脏中心肾移植受者的移植后红细胞增多症
Exp Clin Transplant. 2007 Jun;5(1):607-9.
5
Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.肾移植术后红细胞增多症与微量白蛋白尿的关联:对血管紧张素转换酶抑制的反应
Am J Nephrol. 1995;15(4):318-22. doi: 10.1159/000168856.
6
Factors predisposing to post-renal transplant erythrocytosis: a retrospective study.肾移植术后红细胞增多症的易感因素:一项回顾性研究。
Saudi J Kidney Dis Transpl. 2008 May;19(3):371-7.
7
Ramipril in post-renal transplant erythrocytosis.雷米普利用于肾移植术后红细胞增多症
J Nephrol. 2007 Jan-Feb;20(1):57-62.
8
Angiotensin-converting enzyme inhibitor-induced anemia and treatment for erythrocytosis in renal transplant recipients.血管紧张素转换酶抑制剂所致贫血及肾移植受者红细胞增多症的治疗
Nihon Jinzo Gakkai Shi. 1995 Jun;37(6):343-7.
9
Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.血管紧张素转换酶多态性基因、胰岛素样生长因子-1及其他因素对移植后红细胞增多症患者血细胞比容对依那普利治疗反应率的影响。
Transplant Proc. 2005 Mar;37(2):1012-3. doi: 10.1016/j.transproceed.2004.11.078.
10
Effect of enalapril on exaggerated erythropoietin response to phlebotomy in erythrocytosic renal transplant patients.依那普利对红细胞增多型肾移植患者静脉放血后促红细胞生成素过度反应的影响。
Nephrol Dial Transplant. 1998 Nov;13(11):2884-9. doi: 10.1093/ndt/13.11.2884.

引用本文的文献

1
Management of Pediatric Post-renal Transplant Erythrocytosis With Enalapril: A Case Report.依那普利治疗小儿肾移植术后红细胞增多症:一例报告
Cureus. 2025 Mar 19;17(3):e80850. doi: 10.7759/cureus.80850. eCollection 2025 Mar.
2
Post-transplant erythrocytosis after kidney transplantation: A review.肾移植后移植后红细胞增多症:综述
World J Transplant. 2021 Jun 18;11(6):220-230. doi: 10.5500/wjt.v11.i6.220.
3
Post-transplant erythrocytosis refractory to ACE inhibitors and angiotensin receptor blockers.肾移植后红细胞增多症,对血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂难治。
BMJ Case Rep. 2018 Jun 28;2018:bcr-2018-224622. doi: 10.1136/bcr-2018-224622.
4
Blood disorders typically associated with renal transplantation.与肾移植相关的血液系统疾病。
Front Cell Dev Biol. 2015 Mar 19;3:18. doi: 10.3389/fcell.2015.00018. eCollection 2015.